Pharmaceuticals, Biotechnology and Life Sciences
The European Commission (EC) has granted conditional marketing authorization for Libtayo to treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.
Amid Oasmia’s decision to report certain suspicious transactions that has been made by to company during several years, to the Swedish authority, Sven Rohmann, has today been appointed as acting CEO of the company, to replace the present CEO, Mikael Asp.
Basilea Pharmaceutica has enrolled the first patient in a newly opened cohort in the ongoing FIDES-01 phase 2 registrational study with the panFGFR kinase inhibitor derazantinib in intrahepatic cholangiocarcinoma (iCCA).
Wize Pharma and Cannabics Pharmaceuticals have formed a joint venture (JV), to work on cannabinoid products to treat ophthalmic conditions, Wize said on Friday.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has nodded for extension for Dupixent, following USFDA’s approval for nasal polyposis, enabling its approval in the European Union (EU) to also include adolescents 12 to 17 years of age with moderate-to-severe AD who are candidates for systemic therapy.
Indian Glenmark Pharmaceuticals has been granted final approval by the U.S. FDA for Ezetimibe and Simvastatin Tablets, for several doses.
ImmuPharma has met the primary endpoint in additional study, testing Lupuzor, after requests from Investigators and patients involved in the Pivotal Phase III study, permitting patients who participated in the Phase III study, to receive Lupuzor.
Menarini Ricerche’s study showed that a transmembrane glycoprotein, is robustly expressed in a number of solid tumours, liek pancreatic and…
Regeneron Pharmaceuticals and Sanofi got the approval from the FDA for Dupixent for certain combinations to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
Sanofi’s MenQuadfi Meningococcal Polysaccharide Tetanus Toxoid Conjugate Vaccine candidate to help prevent meningococcal meningitis will be reviewed for BLA by the FDA, expecting to reach the decision on April 25, 2020.